{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Thang M"],"funding":["Eshelman Institute for Innovation, University of North Carolina at Chapel Hill","NCATS","NCATS NIH HHS","National Cancer Institute","NCI NIH HHS","National Institutes of Health","University of North Carolina at Chapel Hill"],"pagination":["200834"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11263637"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["32(3)"],"pubmed_abstract":["Tumor-homing neural stem cell (NSC) therapy is emerging as a promising treatment for aggressive cancers of the brain. Despite their success, developing tumor-homing NSC therapy therapies that maintain durable tumor suppression remains a challenge. Herein, we report a synergistic combination regimen where the novel small molecule TR-107 augments NSC-tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) therapy (hiNeuroS-TRAIL) in models of the incurable brain cancer glioblastoma (GBM) <i>in vitro</i>. We report that the combination of hiNeuroS-TRAIL and TR-107 synergistically upregulated caspase markers and restored sensitivity to the intrinsic apoptotic pathway by significantly downregulating inhibitory pathways associated with chemoresistance and radioresistance in the TRAIL-res"],"journal":["Molecular therapy. Oncology"],"pubmed_title":["Combining the constitutive TRAIL-secreting induced neural stem cell therapy with the novel anti-cancer drug TR-107 in glioblastoma."],"pmcid":["PMC11263637"],"funding_grant_id":["U01 TR003715","F30CA243270","T32 CA071341"],"pubmed_authors":["Kass LE","Hingtgen SD","Daglish S","Fennell EMJ","Mann BE","Mellows C","Mercer-Smith AR","Valdivia A","Thang M","Graves LM"],"additional_accession":[]},"is_claimable":false,"name":"Combining the constitutive TRAIL-secreting induced neural stem cell therapy with the novel anti-cancer drug TR-107 in glioblastoma.","description":"Tumor-homing neural stem cell (NSC) therapy is emerging as a promising treatment for aggressive cancers of the brain. Despite their success, developing tumor-homing NSC therapy therapies that maintain durable tumor suppression remains a challenge. Herein, we report a synergistic combination regimen where the novel small molecule TR-107 augments NSC-tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) therapy (hiNeuroS-TRAIL) in models of the incurable brain cancer glioblastoma (GBM) <i>in vitro</i>. We report that the combination of hiNeuroS-TRAIL and TR-107 synergistically upregulated caspase markers and restored sensitivity to the intrinsic apoptotic pathway by significantly downregulating inhibitory pathways associated with chemoresistance and radioresistance in the TRAIL-res","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Sep","modification":"2026-06-01T20:38:32.262Z","creation":"2025-06-01T01:16:09.665Z"},"accession":"S-EPMC11263637","cross_references":{"pubmed":["39045029"],"doi":["10.1016/j.omton.2024.200834"]}}